300233 Stock Overview
Researches and develops, produces, markets, and sells Cephalosporin intermediates in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Shandong Jincheng Pharmaceutical Group Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥11.22 |
| 52 Week High | CN¥20.50 |
| 52 Week Low | CN¥10.83 |
| Beta | 0.31 |
| 11 Month Change | -17.80% |
| 3 Month Change | -32.61% |
| 1 Year Change | -38.35% |
| 33 Year Change | -64.22% |
| 5 Year Change | -43.56% |
| Change since IPO | 10.16% |
Recent News & Updates
Recent updates
Shandong Jincheng Pharmaceutical Group Co., Ltd's (SZSE:300233) Popularity With Investors Is Under Threat From Overpricing
Jun 07
Shandong Jincheng Pharmaceutical Group's (SZSE:300233) Problems Go Beyond Weak Profit
Apr 04Shandong Jincheng Pharmaceutical Group Co., Ltd's (SZSE:300233) Shares Climb 29% But Its Business Is Yet to Catch Up
Mar 04Shandong Jincheng Pharmaceutical Group (SZSE:300233) Seems To Use Debt Quite Sensibly
Mar 02Shareholder Returns
| 300233 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -22.0% | -4.0% | -2.3% |
| 1Y | -38.4% | -10.0% | -17.3% |
Return vs Industry: 300233 underperformed the CN Pharmaceuticals industry which returned -10.1% over the past year.
Return vs Market: 300233 underperformed the CN Market which returned -18.4% over the past year.
Price Volatility
| 300233 volatility | |
|---|---|
| 300233 Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in CN Market | 8.9% |
| 10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 300233's share price has been volatile over the past 3 months.
Volatility Over Time: 300233's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 3,806 | Jiaquan Li | www.jinchengpharm.com |
Shandong Jincheng Pharmaceutical Group Co., Ltd, together with its subsidiaries, researches and develops, produces, markets, and sells Cephalosporin intermediates in China and internationally. The company offers active pharmaceutical ingredients, biopharmaceuticals, medical intermediates, fine chemicals, finished dosages, and pharmaceutical products. It also provides animal nutrition and health care, as well as CMO and CDMO services.
Shandong Jincheng Pharmaceutical Group Co., Ltd Fundamentals Summary
| 300233 fundamental statistics | |
|---|---|
| Market cap | CN¥4.26b |
| Earnings (TTM) | CN¥203.59m |
| Revenue (TTM) | CN¥3.59b |
20.9x
P/E Ratio1.2x
P/S RatioIs 300233 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300233 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.59b |
| Cost of Revenue | CN¥2.13b |
| Gross Profit | CN¥1.46b |
| Other Expenses | CN¥1.26b |
| Earnings | CN¥203.59m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.54 |
| Gross Margin | 40.61% |
| Net Profit Margin | 5.67% |
| Debt/Equity Ratio | 15.8% |
How did 300233 perform over the long term?
See historical performance and comparison